Τίτλος:
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Daratumumab is a CD38-directed monoclonal antibody approved for treating multiple myeloma (MM). Propensity score matching (PSM) based on individual patient data (IPD) was conducted to compare overall survival (OS) and progression-free survival (PFS) for daratumumab versus real-world standard of care (SOC). IPD for patients with relapsed and refractory (RR) MM treated with daratumumab monotherapy were from the GEN501 and SIRIUS studies; IPD for patients treated with SOC were from an International Myeloma Working Group (IMWG) chart review of patients with RRMM. Prior to PSM, patients treated with daratumumab had significantly longer OS (median 20.1 vs. 10.1 months, hazard ratio [HR] = 0.51 [0.39–0.67]) and PFS (median 4.0 vs. 2.8 months, HR = 0.73 [0.58–0.92]) than patients treated with SOC therapies. After PSM, daratumumab maintained a significantly prolonged OS (19.9 vs. 9.2 months, HR = 0.44 [0.31–0.63]) and PFS (3.9 vs. 1.6 months, HR = 0.56 [0.42–0.74]) compared with SOC. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Kumar, S.
Durie, B.
Nahi, H.
Vij, R.
Dimopoulos, M.A.
Kastritis, E.
Terpos, E.
Leleu, X.
Beksac, M.
Goldschmidt, H.
Hillengass, J.
Su, Z.
Hutton, B.
Cameron, C.
Khan, I.
Lam, A.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
daratumumab; antineoplastic agent; daratumumab; monoclonal antibody, adult; Article; cancer chemotherapy; cancer survival; cohort analysis; comparative effectiveness; controlled study; drug efficacy; female; follow up; health care quality; human; major clinical study; male; medical record review; middle aged; monotherapy; multiple myeloma; overall survival; priority journal; progression free survival; propensity score; comparative study; drug resistance; health care quality; mortality; multiple myeloma; phase 1 clinical trial (topic); phase 2 clinical trial (topic); propensity score; survival analysis; time factor; tumor recurrence, Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Propensity Score; Standard of Care; Survival Analysis; Time Factors
DOI:
10.1080/10428194.2018.1459609
